Syndax Pharmaceuticals (SNDX) Debt to Equity (2020 - 2024)
Syndax Pharmaceuticals (SNDX) has 5 years of Debt to Equity data on record, last reported at $1.19 in Q4 2024.
- For Q4 2024, Debt to Equity changed N/A year-over-year to $1.19; the TTM value through Dec 2024 reached $1.19, changed N/A, while the annual FY2024 figure was $1.19, N/A changed from the prior year.
- Debt to Equity reached $1.19 in Q4 2024 per SNDX's latest filing, up from $0.06 in the prior quarter.
- Across five years, Debt to Equity topped out at $1.19 in Q4 2024 and bottomed at $0.05 in Q4 2021.
- Average Debt to Equity over 4 years is $0.22, with a median of $0.09 recorded in 2021.
- The widest YoY moves for Debt to Equity: up 29.61% in 2021, down 76.03% in 2021.
- A 4-year view of Debt to Equity shows it stood at $0.08 in 2020, then plummeted by 38.36% to $0.05 in 2021, then increased by 13.52% to $0.06 in 2022, then surged by 2036.64% to $1.19 in 2024.
- Per Business Quant database, its latest 3 readings for Debt to Equity were $1.19 in Q4 2024, $0.06 in Q2 2022, and $0.05 in Q1 2022.